Security
Relay Therapeutics, Inc. Common Stock · RLAY
RLAYNASDAQCommon stockCurrentCIK 1812364Updated Oct 31, 2026
RLAY price & chart
Loading TradingView…
NASDAQ:RLAY on TradingView ↗About the company
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs
In the news
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 670,000,000Source | 930,115,000Source | 967,457,000Source | 728,841,000Source | 772,550,000Source | 699,613,000Source | 799,362,000Source | 841,441,000Source | 621,331,000Source | 871,296,000Source | 843,980,000Source | 1,099,771,000Source |
| Property, Plant and Equipment, NetUSD | 2,359,000Source | 7,210,000Source | 862,000Source | 3,461,000Source | 8,350,000Source | 1,222,000Source | 5,148,000Source | 9,875,000Source | 1,726,000Source | 5,911,000Source | 10,901,000Source | 11,634,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 91,564,000Source | 152,357,000Source | 121,189,000Source | 113,941,000Source | 134,125,000Source | 204,589,000Source | 93,542,000Source | 152,866,000Source | 84,018,000Source | 124,287,000Source | 143,736,000Source | 151,794,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 306,000Source |
| Assets, CurrentUSD | 624,014,000Source | 865,129,000Source | 928,082,000Source | 680,392,000Source | 704,270,000Source | 658,462,000Source | 739,659,000Source | 770,100,000Source | 578,279,000Source | 809,204,000Source | 770,103,000Source | 1,019,505,000Source |
| Operating Lease, Right-of-Use AssetUSD | 41,369,000Source | 53,357,000Source | 37,177,000Source | 42,730,000Source | 54,923,000Source | 38,593,000Source | 50,136,000Source | 56,459,000Source | 39,990,000Source | 51,762,000Source | 57,969,000Source | 63,754,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 62,291,000Source | 91,254,000Source | 77,448,000Source | 63,183,000Source | 90,806,000Source | 57,430,000Source | 78,281,000Source | 95,677,000Source | 54,271,000Source | 93,504,000Source | 91,977,000Source | 149,553,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 168,000Source | 167,000Source | 211,000Source | 168,000Source | 133,000Source | 182,000Source | 168,000Source | 132,000Source | 168,000Source | 168,000Source | 127,000Source | 121,000Source |
| Additional Paid in CapitalUSD | 2,566,927,000Source | 2,498,471,000Source | 3,063,118,000Source | 2,551,383,000Source | 2,257,132,000Source | 2,730,233,000Source | 2,536,230,000Source | 2,228,759,000Source | 2,580,928,000Source | 2,516,905,000Source | 2,152,654,000Source | 2,019,126,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,959,879,000Source | -1,662,286,000Source | -2,171,767,000Source | -1,885,730,000Source | -1,574,181,000Source | -2,088,060,000Source | -1,815,355,000Source | -1,481,969,000Source | -2,014,769,000Source | -1,738,290,000Source | -1,400,582,000Source | -1,058,609,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 493,000Source | 2,509,000Source | -1,553,000Source | -163,000Source | -1,340,000Source | -172,000Source | 38,000Source | -1,158,000Source | 733,000Source | -991,000Source | -196,000Source | -10,420,000Source |
| Stockholders' Equity Attributable to ParentUSD | 607,709,000Source | 838,861,000Source | 890,009,000Source | 665,658,000Source | 681,744,000Source | 642,183,000Source | 721,081,000Source | 745,764,000Source | 567,060,000Source | 777,792,000Source | 752,003,000Source | 950,218,000Source |
| Liabilities and EquityUSD | 670,000,000Source | 930,115,000Source | 967,457,000Source | 728,841,000Source | 772,550,000Source | 699,613,000Source | 799,362,000Source | 841,441,000Source | 621,331,000Source | 871,296,000Source | 843,980,000Source | 1,099,771,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 32,605,000Source | 46,968,000Source | 50,804,000Source | 32,525,000Source | 45,043,000Source | 29,751,000Source | 37,052,000Source | 37,144,000Source | 25,578,000Source | 50,729,000Source | 30,269,000Source | 63,709,000Source |
| Operating Lease, Liability, CurrentUSD | 3,643,000Source | 5,529,000Source | 4,014,000Source | 3,525,000Source | 5,335,000Source | 3,888,000Source | 5,930,000Source | 5,147,000Source | 3,765,000Source | 5,727,000Source | 4,964,000Source | 4,276,000Source |
| Accounts Payable, CurrentUSD | 2,752,000Source | 6,867,000Source | 11,459,000Source | 5,176,000Source | 11,167,000Source | 4,104,000Source | 8,450,000Source | 7,973,000Source | 7,705,000Source | 14,097,000Source | 9,211,000Source | 10,578,000Source |
| Operating Lease, Liability, NoncurrentUSD | 29,686,000Source | 44,286,000Source | 26,644,000Source | 30,658,000Source | 45,763,000Source | 27,679,000Source | 41,229,000Source | 47,159,000Source | 28,693,000Source | 42,775,000Source | 48,502,000Source | 53,466,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 25,132,000Source | 33,216,000Source | 34,079,000Source | 23,215,000Source | 27,773,000Source | 20,912,000Source | 20,990,000Source | 22,362,000Source | 13,645,000Source | 21,236,000Source | 14,890,000Source | 22,703,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | — | 7,679,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 10,537,000Source | 19,325,000Source | 62,419,000Source | 94,139,000Source | 86,031,000Source | 56,138,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | -306,000Source | -97,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | — | — | -2,394,000Source | 1,989,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -51,112,000Source | -73,210,000Source | -235,455,000Source | -249,107,000Source | -300,316,000Source | -229,490,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 32,901,000Source | 42,465,000Source | 192,799,000Source | -41,083,000Source | 257,634,000Source | -188,745,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 384,000Source | 410,000Source | 2,018,000Source | 4,126,000Source | 9,062,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 138,782,000Source | — | 1,604,000Source | 270,153,000Source | 34,753,000Source | 289,910,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 120,571,000Source | -30,745,000Source | -41,052,000Source | -20,037,000Source | -7,929,000Source | -128,325,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 93,822,000Source | 154,476,000Source | 122,525,000Source | 116,199,000Source | 205,925,000Source | 95,661,000Source | 85,354,000Source | 126,406,000Source | 146,443,000Source | 154,372,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 22,484,000Source | — | — | — | — | 62,419,000Source | 94,139,000Source | 86,031,000Source | 56,138,000Source |
| DepreciationUSD | — | — | — | — | — | — | 504,000Source | 1,208,000Source | 3,557,000Source | 5,464,000Source | 5,269,000Source | 4,130,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | 101,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -1,003,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 12,129,000Source | 19,750,000Source | 14,691,000Source | 13,627,000Source | 11,027,000Source | 18,739,000Source | 56,710,000Source | 76,592,000Source | 74,950,000Source | 65,978,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 2,300,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -74,149,000Source | -88,105,000Source | -83,707,000Source | -70,375,000Source | -73,291,000Source | -77,065,000Source | -276,479,000Source | -337,708,000Source | -341,973,000Source | -290,509,000Source |
| Operating ExpensesUSD | — | — | 80,391,000Source | 96,369,000Source | 91,174,000Source | 77,524,000Source | 81,590,000Source | 92,548,000Source | 318,093,000Source | 382,475,000Source | 398,546,000Source | 300,656,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 6,242,000Source | 8,264,000Source | 7,117,000Source | 6,472,000Source | 5,299,000Source | 7,804,000Source | 26,259,000Source | 34,760,000Source | 31,027,000Source | 8,766,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 50,899,000Source | 21,971,000Source | 122,971,000Source | 650,629,000Source | 385,542,000Source | 535,419,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 350,000Source | 677,000Source | 3,000,000Source | 7,679,000Source | 15,355,000Source | 10,007,000Source | 25,546,000Source | 1,381,000Source |
| Operating Income (Loss)USD | — | — | -80,391,000Source | -96,369,000Source | -90,824,000Source | -76,847,000Source | -78,590,000Source | -84,869,000Source | -302,738,000Source | -372,468,000Source | -373,000,000Source | -299,275,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 6,242,000Source | 8,264,000Source | 7,117,000Source | 6,472,000Source | 5,299,000Source | 7,804,000Source | 26,259,000Source | 34,760,000Source | 31,027,000Source | 8,766,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -74,149,000Source | -88,105,000Source | -83,707,000Source | -70,375,000Source | -73,291,000Source | -77,065,000Source | -276,479,000Source | -337,708,000Source | -341,973,000Source | -290,509,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.43Source | -0.63Source | -0.41Source | -0.41Source | -0.41Source | -0.46Source | -1.61Source | -2.36Source | -2.79Source | -2.59Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.43Source | -0.63Source | -0.41Source | -0.41Source | -0.41Source | -0.46Source | -1.61Source | -2.36Source | -2.79Source | -2.59Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 172,389,209Source | 140,229,056Source | 202,849,466Source | 171,264,622Source | 179,849,137Source | 169,233,155Source | 171,586,558Source | 142,867,844Source | 122,576,527Source | 112,233,649Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | — | — | — | 112,233,649Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 12,129,000Source | 19,750,000Source | 14,691,000Source | 13,627,000Source | 11,027,000Source | 18,739,000Source | 56,710,000Source | 76,592,000Source | 74,950,000Source | 65,978,000Source |
| Interest Income, OtherUSD | — | — | 6,407,000Source | 8,274,000Source | 7,115,000Source | 7,105,000Source | 5,352,000Source | 7,813,000Source | 27,035,000Source | 34,746,000Source | 31,045,000Source | 8,786,000Source |
| Operating ExpensesUSD | — | — | 80,391,000Source | 96,369,000Source | 91,174,000Source | 77,524,000Source | 81,590,000Source | 92,548,000Source | 318,093,000Source | 382,475,000Source | 398,546,000Source | 300,656,000Source |
| Other Expenses | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
Filing attachments
rlay-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 3 rlay-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay Therapeutics, Inc. (the “Company”) and TD Securities (USA) LLC (the “Agent”). Capitalized terms used but not otherwise defined herein shall have the respective meani…
Read attachment ↗rlay-ex99_2.htm · 8-K · 2026-08-06
EX-99.2 4 rlay-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented initial positive clinical data from Phase 1/2 ReInspire trial in vascular anomalies at the ISSVA World Congress 2026 and opened expa…
Read attachment ↗rlay-ex99_1.htm · 8-K · 2026-05-19
EX-99.1 2 rlay-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported outcomes show 89% and 79% of patients achi…
Read attachment ↗rlay-ex99_2.htm · 8-K · 2026-05-19
EX-99.2 3 rlay-ex99_2.htm EX-99.2 Vascular Anomalies Update May 2026 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the progress, timing and results of the clinical development of the programs across our portfolio, including the expected timing of data readout and other clinical and developmental milest…
Read attachment ↗rlay-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 rlay-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced patients at ESMO TAT, demonstrating 11.1-month median PFS with similar efficacy in kinase and non-kinas…
Read attachment ↗rlay-ex99_1.htm · 8-K · 2026-04-27
EX-99.1 2 rlay-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is simil…
Read attachment ↗